Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: A randomized, controlled trial

Europace

Volumn 19, Issue 4, 2017, Pages 602-606

  Katritsis, Demosthenes G ^a,b   Zografos, Theodoros ^b   Katritsis, George D ^c   Giazitzoglou, Eleftherios ^b   Vachliotis, Vasilios ^b   Paxinos, George ^b   Camm, A John ^d   Josephson, Mark E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Athens Euroclinic   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ablation; Antiarrhythmic drugs; Atrioventricular nodal re entrant tachycardia; Randomized controlled trial

Indexed keywords

ADENOSINE; BISOPROLOL; DILTIAZEM; PROPRANOLOL; VERAPAMIL; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA; CARDIOVERSION; CAROTID SINUS MASSAGE; CATHETER ABLATION; CONTROLLED STUDY; FEMALE; FLUID RESUSCITATION; FOLLOW UP; HEART ELECTROPHYSIOLOGY; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VALSALVA MANEUVER; ADOLESCENT; DRUG COMBINATION; LONGITUDINAL STUDY; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; BISOPROLOL; CATHETER ABLATION; DILTIAZEM; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TACHYCARDIA, ATRIOVENTRICULAR NODAL REENTRY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019114811     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw064     Document Type: Article

References (22)

1. Mauritson DR, Winniford MD, Walker WS, Rude RE, Cary JR, Hillis LD. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med 1982;96:409-12.
2. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventri-cular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984;54:1138-9.
3. Talajic M, Papadatos D, Villemaire C, Nayebpour M, Nattel S. Antiarrhythmic actions of diltiazem during experimental atrioventricular reentrant tachycardias. Importance of use-dependent calcium channel-blocking properties. Circulation 1990;81:334-42.
4. Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fuca G et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001;37:548-53.
5. Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett EL. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The flecainide supraventri-cular tachycardia study group. Am J Cardiol 1994;74:578-84.
6. Dorian P, Naccarelli GV, Coumel P, Hohnloser SH, Maser MJ. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The flecainide multicenter investigators group. Am J Cardiol 1996;77: 89A-95A.
7. Chimienti M, Cullen MT Jr, Casadei G. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyar-rhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 1995;16:1943-51.
8. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propa-fenone PSVT Study Group. Circulation 1995;92:2550-7.
9. Wanless RS, Anderson K, Joy M, Joseph SP. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J 1997;133:441-6.
10. Tendera M, Wnuk-Wojnar AM, Kulakowski P, Malolepszy J, Kozlowski JW, Krzeminska-Pakula M et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J 2001;142:93-8.
11. Farkowski MM, Pytkowski M, Maciag A, Golicki D, Wood KA, Kowalik I et al. Gender-related differences in outcomes and resource utilization in patients undergoing radiofrequency ablation of supraventricular tachycardia: Results from patients' perspective on radiofrequency catheter ablation of AVRT and AVNRT study. Europace 2014;16:1821-1827.
12. Goldberg AS BM, Mickelsen S, Nawman R, West G, Kusumoto FM. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol 2002;89:1120-3.
13. Bohnen M, Stevenson WG, Tedrow UB, Michaud GF, John RM, Epstein LM et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm 2011;8:1661-6.
14. Cheng CH, Sanders GD, Hlatky MA, Heidenreich P, McDonald KM, Lee BK et al. Cost effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000;133:864-76.
15. Kalbfleisch SJ, Calkins H, Langberg JJ, el-Atassi R, Leon A, Borganelli M et al. Comparison of the cost of radiofrequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1992;19:1583-7.
16. D'Este D, Zoppo F, Bertaglia E, Zerbo F, Picciolo A, Scarabeo V et al. Long-term outcome of patients with atrioventricular node reentrant tachycardia. Int J Cardiol 2007;115:350-3.
17. Yeh SJ, Lin FC, Chou YY, Hung JS, Wu D. Termination of paroxysmal supraventri-cular tachycardia with a single oral dose of diltiazem and propranolol. Circulation 1985;71:104-9.
18. Kalbfleisch SJ, Strickberger SA, Williamson B, Vorperian VR, Man C, Hummel JD et al. Randomized comparison of anatomic and electrogram mapping approaches to ablation of the slow pathway of atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1994;23:716-23.
19. Giazitzoglou E, Korovesis S, Kokladi M, Venetsanakos I, Paxinos G, Katritsis DG. Slow-pathway ablation for atrioventricular nodal re-entrant tachycardia with no risk of atrioventricular block. Hellenic J Cardiol 2010;51:407-12.
20. Katritsis DG, Giazitzoglou E, Zografos T, Ellenbogen KA, Camm AJ. An approach to left septal slow pathway ablation. J Interv Card Electrophysiol 2011;30:73-9.
21. Brembilla-Perrot B, Sellal JM, Olivier A, Manenti V, Beurrier D, de Chillou C et al. Recurrences of symptoms after AV node re-entrant tachycardia ablation: a clinical arrhythmia risk score to assess putative underlying cause. Int J Cardiol 2015;179: 292-6.
22. Chen H, Shehata M, Ma W, Xu J, Cao J, Cingolani E et al. Atrioventricular block during slow pathway ablation: entirely preventable? Circ Arrhythm Electrophysiol 2015;8:739-44.